Sign In
Buy CRSP
$53.51
-0.0100 (-0.0187%)
At Close: Aug 10, 2026
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
04:07pm, Monday, 10'th Aug 2026
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announce
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
10:09am, Wednesday, 05'th Aug 2026
CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
12:00pm, Tuesday, 04'th Aug 2026
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Monday, 03'rd Aug 2026
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
04:15pm, Monday, 03'rd Aug 2026
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
06:50pm, Thursday, 30'th Jul 2026
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
05:38pm, Thursday, 30'th Jul 2026
CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon.
3 Stocks With the Most Upside by the End of 2026
04:30pm, Thursday, 30'th Jul 2026
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 28'th Jul 2026
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:03am, Monday, 27'th Jul 2026
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
06:51pm, Friday, 24'th Jul 2026
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
05:30am, Wednesday, 22'nd Jul 2026
Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therapeutics for a couple of the firm's funds. While it's typically considered a gene-editing play (and ev
CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.
03:14am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Secur
Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead
02:02am, Tuesday, 21'st Jul 2026
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high,
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
11:51am, Monday, 20'th Jul 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
